Ojio, Hidenori
Tanaka, Yoshihiro http://orcid.org/0000-0002-0300-7924
Sato, Yuta
Imai, Takeharu
Okumura, Naoki
Matsuhashi, Nobuhisa
Takahashi, Takao
Yoshida, Kazuhiro
Article History
Received: 29 September 2020
Accepted: 8 November 2020
First Online: 27 November 2020
Compliance with ethical standard
:
: Dr. Yoshida reports receipt of grants, personal fees and non-financial support from EA Pharma Co., Ltd., Sanofi, Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., and Novartis Pharma K.K.; and grants from Kyowa Hakko Kirin Co., Ltd. outside of the submitted work. Dr. Tanaka reports receipt of grants from Daiichi Sankyo Co., Ltd. outside of the submitted work. Other authors have no conflict of interest to disclose. The funding source had no role in the design, practice, or analysis of this study.
: All procedures performed in the study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments.
: Informed consent was obtained from the patient for being included in the study.